[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585377":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":39,"responsibleParty":55,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":11,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm","EXPERIMENTAL",null,[13],"Drug: Kuangxiong Aerosol",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo Drug",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Kuangxiong Aerosol","Patients in the intervention group will receive Kuangxiong Aerosol for eight weeks, in addition to guideline-recommended medications. The aerosol will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo Drug","Patients in the control group will receive a placebo version of Kuangxiong Aerosol for eight weeks, alongside guideline-recommended medications. The placebo will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Xianlun Li","CONTACT","13910812495","lixianlun@hotmail.com",{"name":36,"role":32,"phone":37,"phoneExt":11,"email":38},"Danni Wu","13502622048","wudanni@student.pumc.edu.cn",[40],{"facility":5,"status":11,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Beijing","Chaoyang District","100029","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53,54],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"name":36,"role":32,"phone":37,"phoneExt":11,"email":38},{"type":56,"investigatorFullName":31,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100585377","phase-4-clinical-evaluation-of-aromatic-wentong-in-the-treatment-of-coronary-microvascular-disease-100585377",false,"NCT06901570","Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease","Clinical Assessment of Aromatic Wentong for Coronary Microvascular Disease Management","Inclusion Criteria:\n\n* Aged between 18 and 80 years, regardless of gender.\n* Clinical symptoms of myocardial ischemia.\n* Objective evidence of myocardial ischemia, including:\n\n  1. ECG changes during chest pain episodes,\n  2. Stress test-induced chest pain symptoms and\u002For abnormal myocardial blood flow and\u002For abnormal cardiac wall motion with ischemic ECG changes.\n* Coronary angiography (CAG) showing \\>50% reduction in the diameter of the epicardial coronary artery.\n* QFR \\> 0.80 and AMR \\> 2.5 mmHg·s\u002Fcm.\n* Discontinuation of all Chinese medicine interventions for at least two weeks prior to enrollment.\n* Provision of informed consent and a signed informed consent form.\n\nExclusion Criteria:\n\n* Significant liver or kidney dysfunction, defined as ALT, AST, or blood creatinine levels \\>3 times the upper limit of normal.\n* Severe cardiac conditions, including heart failure, myocarditis, cardiomyopathy, acute pericarditis, structural heart disease.\n* Severe systemic diseases, such as severe mental illness, hematopoietic system disorders, or malignant tumors.\n* Suspected or confirmed allergy to the trial drug.\n* Individuals deemed by researchers to be unsuitable for participation in the clinical trial.\n* Women who are pregnant, planning to become pregnant, or currently lactating.","ALL","18 Years","80 Years",{"count":69,"type":70},528,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","Coronary Microvascular Disease (CMD) is a condition where patients experience chest pain (angina) even though their coronary arteries appear normal on angiography. It is common among people with coronary heart disease, especially those with chest pain as their main symptom. Unfortunately, there are no effective treatments available for these patients, and symptoms like chest tightness and persistent pain greatly affect their quality of life.\n\nTraditional Chinese Medicine (TCM) suggests that the root cause of microvascular disease is blocked collateral blood vessels. Aromatic Wentong, a TCM approach, aims to improve blood flow and relieve blockages. Kuangxiong Aerosol is a Chinese patent medicine developed based on the principles of Aromatic Wentong.\n\nThis study is a multicenter, randomized, double-blind, placebo-controlled trial involving 528 patients with chest pain and suspected CMD. Participants are recruited from several hospitals, including China-Japan Friendship Hospital, Fuwai Hospital, and Xiyuan Hospital. Patients are randomly divided into two groups:\n\nThe intervention group receives standard guideline-recommended treatment plus Kuangxiong Aerosol.\n\nThe control group receives standard treatment plus a placebo version of Kuangxiong Aerosol.\n\nThe treatment lasts for 8 weeks.",[76],"Coronary Microvascular Disease","NOT_YET_RECRUITING","2025-04-09",{"date":80,"type":81},"2025-04-11","ACTUAL",{"date":83,"type":70},"2025-04",{"date":85,"type":70},"2028-07",{"name":5,"class":6},1]